Literature DB >> 23836147

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Rodney A Rosalia1, Esther D Quakkelaar, Anke Redeker, Selina Khan, Marcel Camps, Jan W Drijfhout, Ana Luisa Silva, Wim Jiskoot, Thorbald van Hall, Peter A van Veelen, George Janssen, Kees Franken, Luis J Cruz, Angelino Tromp, Jaap Oostendorp, Sjoerd H van der Burg, Ferry Ossendorp, Cornelis J M Melief.   

Abstract

The efficiency of antigen (Ag) processing by dendritic cells (DCs) is vital for the strength of the ensuing T-cell responses. Previously, we and others have shown that in comparison to protein vaccines, vaccination with synthetic long peptides (SLPs) has shown more promising (pre-)clinical results. Here, we studied the unknown mechanisms underlying the observed vaccine efficacy of SLPs. We report an in vitro processing analysis of SLPs for MHC class I and class II presentation by murine DCs and human monocyte-derived DCs. Compared to protein, SLPs were rapidly and much more efficiently processed by DCs, resulting in an increased presentation to CD4⁺ and CD8⁺ T cells. The mechanism of access to MHC class I loading appeared to differ between the two forms of Ag. Whereas whole soluble protein Ag ended up largely in endolysosomes, SLPs were detected very rapidly outside the endolysosomes after internalization by DCs, followed by proteasome- and transporter associated with Ag processing-dependent MHC class I presentation. Compared to the slower processing route taken by whole protein Ags, our results indicate that the efficient internalization of SLPs, accomplished by DCs but not by B or T cells and characterized by a different and faster intracellular routing, leads to enhanced CD8⁺ T-cell activation.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen presentation/processing; CD8 T cells; Cellular immunology; Dendritic cells

Mesh:

Substances:

Year:  2013        PMID: 23836147     DOI: 10.1002/eji.201343324

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  69 in total

Review 1.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

3.  DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Authors:  Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; André Maaske; Vladimir Temchura; Vanessa Heinecke; Drew Hannaman; Jan Buer; Christina Ehrhardt; Wiebke Hansen; Klaus Überla; Matthias Tenbusch
Journal:  Immunology       Date:  2015-04-30       Impact factor: 7.397

4.  Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.

Authors:  Sunil Singhal; Jason Stadanlick; Michael J Annunziata; Abhishek S Rao; Pratik S Bhojnagarwala; Shaun O'Brien; Edmund K Moon; Edward Cantu; Gwenn Danet-Desnoyers; Hyun-Jeong Ra; Leslie Litzky; Tatiana Akimova; Ulf H Beier; Wayne W Hancock; Steven M Albelda; Evgeniy B Eruslanov
Journal:  Sci Transl Med       Date:  2019-02-13       Impact factor: 17.956

5.  The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.

Authors:  Alice Gutjahr; Laura Papagno; Francesco Nicoli; Tomohiro Kanuma; Nozomi Kuse; Mariela Pires Cabral-Piccin; Nicolas Rochereau; Emma Gostick; Thierry Lioux; Eric Perouzel; David A Price; Masafumi Takiguchi; Bernard Verrier; Takuya Yamamoto; Stéphane Paul; Victor Appay
Journal:  JCI Insight       Date:  2019-04-04

6.  Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

Authors:  Erminia Massarelli; William William; Faye Johnson; Merrill Kies; Renata Ferrarotto; Ming Guo; Lei Feng; J Jack Lee; Hai Tran; Young Uk Kim; Cara Haymaker; Chantale Bernatchez; Michael Curran; Tomas Zecchini Barrese; Jaime Rodriguez Canales; Ignacio Wistuba; Lerong Li; Jing Wang; Sjoerd H van der Burg; Cornelis J Melief; Bonnie Glisson
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

7.  Immune Response Resetting in Ongoing Sepsis.

Authors:  Alexandre E Nowill; Márcia C Fornazin; Maria C Spago; Vicente Dorgan Neto; Vitória R P Pinheiro; Simônia S S Alexandre; Edgar O Moraes; Gustavo H M F Souza; Marcos N Eberlin; Lygia A Marques; Eduardo C Meurer; Gilberto C Franchi; Pedro O de Campos-Lima
Journal:  J Immunol       Date:  2019-07-29       Impact factor: 5.422

8.  Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

Authors:  Eleni Maria Varypataki; Koen van der Maaden; Joke Bouwstra; Ferry Ossendorp; Wim Jiskoot
Journal:  AAPS J       Date:  2014-11-12       Impact factor: 4.009

Review 9.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 10.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.